- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00696930
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
November 24, 2015 updated by: Molecular Insight Pharmaceuticals, Inc.
A Phase II Open-label Multi-center Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Subjects will be screened to determine OctreoScan® uptake.
And upon meeting the eligibility criteria, 90 subjects will complete a symptom assessment scale at baseline and throughout the study at specific time points.
Actual treatment will consist of three six-week cycles of a fixed total dose of 13.3 GBq (360 mCi) of 90Y-SMT487.
The total dose will be divided into three equal doses and administered as a single activity of 4.4 GBq (120 mCi) of 90Y-SMT487 once every six weeks for three cycles.
An amino acid infusion will be administered along with each dose.
Long-term follow up will occur at 6 and 12 months after Day 1/ Cycle 1. Survival will be assessed every six months.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Life expectancy > 6 months.
- Subjects must have distant metastases.
- Subjects must be able to discontinue Sandostatin LAR treatment for at least 1 month prior to Day 1/Cycle 1; last dose of Sandostatin LAR must be 60 days or more prior to the first OctreoTher™ dose. For subcutaneous Sandostatin discontinuation should be 12 hours. Subjects taking other long acting somatostatin analogues must discontinue the analogue at least 2 times the dosing interval.
- Upon baseline disease assessment, all subjects must have at least 1 measurable site of disease that either has never been irradiated or if the measurable lesion has been previously irradiated; this same lesion has since demonstrated progression base don the SWOG response criteria.
- Subjects must state or agree with the statement that "I have symptoms from my cancer that bother me." Subjects must have failed to gain complete symptom control despite an optimal attempt at somatostatin therapy in the judgement of their physician.
Exclusion Criteria:
- Chemotherapy, biologic therapy or other investigational therapy within 4 weeks of Day 1.
- Surgery, hormonal therapy (not including somatostatin analogues) or radiation, within 2 weeks of Day 1.
- Subjects with know brain metastases unless these metastases have been treated and stabilized for at least six months prior to study start.
- Subjects who received high dose OctreoScan therapy or other radiolabelled somatostatin therapy or other systemic radiolabelled therapy (e.g. MIBG) for treatment of metastatic carcinoid.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
June 11, 2008
First Submitted That Met QC Criteria
June 12, 2008
First Posted (Estimate)
June 13, 2008
Study Record Updates
Last Update Posted (Estimate)
November 26, 2015
Last Update Submitted That Met QC Criteria
November 24, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSMT 487A 2202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Carcinoid Tumor
-
National Cancer Institute (NCI)CompletedMetastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Regional Gastrointestinal Carcinoid TumorUnited States
-
Crinetics Pharmaceuticals Inc.Active, not recruitingCarcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of PancreasUnited States, Brazil, Argentina, Canada, Mexico, Peru, Poland
-
M.D. Anderson Cancer CenterRecruitingCarcinoid Tumor | Carcinoid Syndrome | Metastatic Carcinoid Tumor | Digestive System Neuroendocrine Tumor G1United States
-
Mid-Atlantic Oncology ProgramCancer Biotherapy Research GroupCompletedLung Cancer | Gastrointestinal Carcinoid TumorUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid TumorCanada
-
National Cancer Institute (NCI)TerminatedGastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Regional Gastrointestinal Carcinoid Tumor | Pulmonary Carcinoid TumorUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedGastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid TumorUnited States
-
Vanderbilt-Ingram Cancer CenterEntrinsic Bioscience Inc.TerminatedNeuroendocrine Tumor | Carcinoid SyndromeUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedIslet Cell Tumor | Gastrointestinal Carcinoid TumorUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)CompletedIslet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic SyndromeUnited States
Clinical Trials on 90Y-SMT487
-
Pentixapharm AGRecruiting
-
Masonic Cancer Center, University of MinnesotaTerminatedAcute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Ochsner Health SystemBoston Scientific CorporationRecruitingCarcinoma, HepatocellularUnited States
-
French Innovative Leukemia OrganisationTerminated
-
Gilead SciencesWithdrawnDiffuse Large B-cell Lymphoma | NHL | Non Hodgkin's Lymphoma | Aggressive NHLUnited States
-
Lund University HospitalBayerCompleted
-
University of Warmia and MazuryStowarzyszenie Pacjentów i Osób Wspierających Chorych na Guzy NeuroendokrynneUnknown
-
The Christie NHS Foundation TrustRecruiting
-
SCRI Development Innovations, LLCSirtex MedicalCompleted
-
David BushnellNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden...Active, not recruitingNeuroendocrine Tumor Gastrointestinal, Hormone-Secreting | Neuroendocrine Tumor, MalignantUnited States